Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

Drug Dosing: Obese Patients

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...

Drug Administration and Therapy Phases: Overview

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

PDE5A variation is associated with tadalafil response in men with diabetes mellitus and erectile dysfunction: a prospective proof-of-concept pharmacogenetic study.

The journal of sexual medicine·2026

Same author

Unmasking Indolent Systemic Mastocytosis in Patients with Unexplained or Treatment-Refractory Osteoporosis: A Case Series with Diagnostic and Therapeutic Implications.

Biomolecules·2026

Same author

Pharmacogenomic Stratification for Oncology Drug Repurposing: An Exposure Target Context Eligibility Framework.

Pharmaceuticals (Basel, Switzerland)·2026

Same author

Obesity-Related Functional Hypogonadism Requires Therapeutic Recalibration: Implications for GLP-1-Based Therapies.

Andrology·2026

Same author

Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map.

Drugs·2026

Same author

Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026

Search research articles

Related Experiment Video

Updated: May 29, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Tirzepatide data: safety first is safety always!

Miodrag Janić^1,2,3, Syed Arman Rabbani⁴, Mohamed El-Tanani⁴

¹Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia.

Expert Opinion on Drug Safety

|May 27, 2026

Summary

This summary is machine-generated.

Tirzepatide effectively treats type 2 diabetes and obesity. However, understanding its safety profile, including gastrointestinal risks and impact on muscle mass, is crucial for safe and effective use.

Keywords:

Adverse (side) effects muscle loss obesity safety tirzepatide type 2 diabetes

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Related Experiment Videos

Last Updated: May 29, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Multidisciplinary Approach to Obesity Management: A Case Report

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Area of Science:

Metabolic disease research
Pharmacology
Clinical safety evaluation

Background:

Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates significant efficacy in managing type 2 diabetes and obesity.
The widespread adoption of tirzepatide necessitates a comprehensive understanding of its safety profile.

Purpose of the Study:

To evaluate the current evidence on the efficacy, safety, and metabolic effects of tirzepatide.
To examine the drug's tolerability, including common and rare adverse events, and its impact on skeletal muscle mass.

Main Methods:

A literature search was performed using PubMed and other public databases.
Evidence from clinical trials and real-world data was analyzed.

Main Results:

Tirzepatide shows substantial benefits in glycemic control and weight reduction.
Common gastrointestinal events and treatment discontinuation are noted, alongside rare risks like gallbladder and thyroid disorders.
The drug's impact on skeletal muscle mass requires careful consideration.

Conclusions:

Tirzepatide marks a significant advancement in metabolic therapy.
Personalized patient management and risk-benefit assessment are essential.
Future research should focus on long-term functional outcomes to prevent treatment-induced sarcopenia.